Our life sciences investment strategy
At the Forefront of Life Sciences Innovations for Decades — with Europe’s Largest Biotech VC Fund
EQT Life Sciences has a 30-year history of backing transformative innovations that address some of the world’s most pressing healthcare challenges. We invest in companies focused on the development of therapeutics, medical devices and enabling technologies globally.
Driven by a highly experienced, specialist and stable team that combines scientific expertise with deep commercial experience, we are well positioned to drive healthcare investing in Europe and beyond.
Investment Approach
There is an increasing need for better medical solutions. This, combined with an ongoing wave of biomedical and technological innovation and a cash-rich Pharma industry facing a looming patent cliff, opens a window of opportunity for specialized investors to create value.
The European market is especially attractive, with a maturing and highly innovative life sciences ecosystem that is structurally underfunded and under-competed.
EQT Life Sciences has a disciplined, high-conviction approach focused on therapeutics across indications, early- to late-stage, with a clearly defined investment criteria, all supported by strong dealflow and a trusted reputation built over decades. The team typically takes a leading role in investment syndicates and a board seat post-investment, providing active strategic and commercial support to position companies for success. This includes pro-active exit planning and leveraging of our expansive network making early connections to pharma to lay the groundwork for future acquisitions.
Turning breakthrough science into real-world impact
Innovative medicines are providing previously unimaginable life-changing impact to patients’ lives.
Through its portfolio companies, EQT Life Sciences currently has ~150 products in clinical trials globally and has brought >115 products to market across different disease indications.
The Life Sciences funds will invest across three key themes that have clear impact potential:
- Addressing unmet medical need through innovation;
- Increasing access to and/or affordability of care for all; and
- Improving quality of care and patient outcomes.
Featured Companies within
Life Sciences Core
Innovations that are designed to improve the quality of life for people with rare diseases.
Amolyt Pharma is dedicated to creating treatment options that significantly improve the quality of life for individuals with rare endocrine disorders.
Founded by a team with extensive experience in both peptide drug development and the endocrine therapeutic area, Amolyt combines deep scientific expertise with an unwavering focus on patient needs. The company’s lead program is a groundbreaking therapy currently in late-stage clinical trials for hypoparathyroidism, a severe condition characterized by calcium imbalance. Existing treatments often carry long-term risks, such as kidney damage or adverse effects on bone health, posing additional challenges for a population already predisposed to osteoporosis due to age and gender factors.
Amolyt’s innovative approach addresses these issues by restoring calcium balance in a more physiological and effective manner, potentially offering a transformative solution without the complications associated with traditional therapies. By tackling these critical unmet needs, Amolyt Pharma is aimed at redefining care for hypoparathyroidism and setting a new standard in endocrine disorder treatment.
Sector
Life Sciences
Country
France
Fund
LSP 6
Entry
2019
Exit
2024
ImCheck
Imcheck Therapeutics is dedicated to developing innovative immuno-oncology therapies to activate immune cells, namely γδ T cells, against both solid and blood cancers.
Their leading candidate, ICT01, is an anti-BTN3A monoclonal antibody that stimulates γ9δ2 T cells, which play a key role at the crossroads of innate and adaptive immunity. Activated γ9δ2 T cells can penetrate tumors and destroy cancer cells directly, as well as indirectly by releasing cytokines that attract other immune cells. These critical features position γ9δ2 T cells as prime targets for next-generation cancer immunotherapies.
Founded on scientific foundation by Prof. D. Olive (Institute Paoli-Calmette, Marseilles) and lead by a seasoned entrepreneur with industry background, Pierre d'Epenoux, Imcheck has developed trials in Acute Myeloid Leukemia (AML) a form of leukemia in adults, at the diagnosis of the disease, in addition to the standard of care, doubling the response rate and prolonging the life of these patients.
These results create important advances in a new immuno-oncology field, with a first success in hematology and a potential to broaden the clinical benefit across solid tumors.
Sector
Life Sciences
Country
France
Fund
LSP 5
Entry
2017
Exit
2025
Website
VarmX
VarmX is a Netherlands-based biotechnology company developing VMX-C001, a novel bypass agent designed to restore coagulation in patients on Factor Xa direct oral anticoagulants (FXa DOACs) - targeting a major unmet need in bleeding management and urgent surgery.
Founded in 2016 as a spin-out from Leiden University Medical Center (LUMC) under Professor Pieter Reitsma, VarmX has secured a strategic collaboration and exclusive acquisition option with CSL Limited, with the deal valued at up to USD 2.2 billion.
With regulatory clearances and a global Phase 3 trial underway, VarmX is positioned to deliver a breakthrough agent in the coagulation space.
Sector
Life Sciences
Country
Netherlands
Fund
LSP 6
Entry
2020
Website
Neuravi
Neuravi, founded in 2009, has developed an innovative stroke treatment that significantly enhances patient outcomes by preserving abilities and saving lives.
The company’s flagship device, the EmboTrap, is specifically designed to efficiently remove clots from the brain — the primary cause of strokes — thereby facilitating recovery. In 2017 and just two years after receiving its initial investment by EQT Life Sciences, Neuravi was acquired by Johnson & Johnson. Today, EmboTrap devices are widely used to treat patients in both Europe and the United States.
Sector
Life Sciences
Country
Ireland
Fund
LSP 5, LSP HEF 1
Entry
2015
Exit
2017
A trusted partner for production of Ac-225
PanTera is a Belgian company specializing in the production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope used in targeted cancer therapies.
Established in 2022 as a joint venture between Ion Beam Applications (IBA) and the Belgian Nuclear Research Centre (SCK CEN), and since 2024 backed by EQT Life Sciences. PanTera aims to enhance the accessibility of innovative cancer treatments by ensuring a reliable supply of Ac-225.To achieve this, PanTera is constructing a state-of-the-art production facility in Mol, Belgium.
Their unique production process involves transforming radium-226 into high-purity Ac-225. This method emphasizes sustainability by recycling and reusing radium, reflecting the company's commitment to environmentally friendly practices.
Sector
Life Sciences
Country
Belgium
Fund
LSP 7
Entry
2024
Website
Meet the Team
News
Discover Our Work in Life Sciences
Learn more about our approach to collaboration and innovation in life sciences.
Exclusive News and Insights Every Week
Add your email address below to sign up for our EQT newsletters.